A study to investigate the effect of taking CoenzymeQ10 supplements on abnormal artery blood vessel function in people with Type 2 diabetes who are on best-dose treatment with statin medication.
- Conditions
- Endothelial dysfunction in Type 2 DiabetesMetabolic and Endocrine - Diabetes
- Registration Number
- ACTRN12605000250639
- Lead Sponsor
- Pfizer CVL grant
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 25
Subjects with type 2 diabetes; treatment with HMG-CoA reductase inhibitor (statin) at a stable dose for 6 weeks; fasting LDL-cholesterol<2.5mmol/L; brachial artery FMD 5.50% on screening ultrasound.
At screening: daytime insulin treatment (nocte insulin permitted); uncontrolled hyperglycaemia (HbA1c level>8.5%); uncontrolled hypertension (resting BP>150/90mmHg); total fasting cholesterol 6.0mmol/L or triglycerides 3.0mmol/L; treatment with other lipid-regulating medications (eg. fibrate, ezetimibe, cholestyramine, niacin, fish oil) or with CoQ supplements (within previous 6 weeks); current treatment with warfarin, nitrate or PDE5-inhibitor (eg. sildenafil); recent cardiovascular event (within previous 6 months); atrial fibrillation or other significant dysrhythmia; significantly abnormal renal, liver or thyroid function; significant anaemia; current smoker (previous 6 months); ethanol intake>21 standard drinks/week; significant substance abuse, psychiatric illness or likely poor compliance with study protocol; any other serious illness (eg. cancer) or likelihood of not completing study; technical difficulty with obtaining ultrasound scan of sufficient quality; weight>150kg.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method